晚期食管鳞癌免疫治疗的现状与未来方向  

Current Status and Future Directions of Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma

作　　者：马晓露 万明宇 钱炯[1] 沈洁[1] 丁永锋 陈肖予 徐农[1] MA Xiao-lu;WAN Ming-yu;QIAN Jiong;SHEN Jie;DING Yong-feng;CHEN Xiao-yu;XU Nong(The First Affiliated Hospital,Zhejiang University,School of Medicine,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院,浙江杭州310003

出　　处：《中国肿瘤》2023年第2期138-147,共10页China Cancer

摘　　要：食管鳞状细胞癌(esophageal squamous cell carcinoma,ESCC)是消化道最具侵袭性的恶性肿瘤之一。我国ESCC的发病率和死亡率均处于全球前列,总体生存率低。因此,迫切需要新的治疗手段改善ESCC尤其是确诊为晚期患者的预后。近年来以免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)为代表的免疫治疗在ESCC全身治疗领域取得了明显进展,随着临床试验不断推进,免疫治疗显现出巨大的应用前景。全文就晚期ESCC免疫治疗的现状及未来的方向作一综述。Esophageal squamous cell carcinoma(ESCC) is one of the most invasive malignant tumors of the digestive tract,whose incidence and mortality rates in China are among the highest worldwide,and the overall survival rate is low.Therefore,it is an urgent need for new treatment methods to improve the prognosis of ESCC patients,especially those diagnosed with advanced disease.In recent years,immunotherapy represented by immune checkpoint inhibitors(ICIs) has made significant progress in the field of systemic treatment of ESCC.With the continued advancement of clinical trials,immunotherapy shows great application prospects.This article reviews the current status and future directions for immunotherapy in advanced ESCC.

关 键 词：食管鳞状细胞癌 免疫治疗 临床试验 

分 类 号：R735.1[医药卫生—肿瘤]